Dupixent 获批用于 CSU 治疗,这是其在治疗与 2 型炎症相关疾病方面的又一重大突破。目前,Dupixent 已获批的适应症还包括特应性皮炎、哮喘、慢性鼻 - 鼻窦炎伴鼻息肉、嗜酸性食管炎、结节性痒疹和慢性阻塞性肺疾病(COPD)。在全球范围内,Du...
The drug is now approved in the European Union (EU) as an add-on maintenance treatment for adults with uncontrolled chronic obstructive pulmonary disease (COPD), characterized by raised blood eosinophils. The approval of the COPD indication represents the sixth approved indication for Dupixent in the...
Regeneron and SanofiwonFDA approval for Dupixent in COPD in late September 2024. The approval of the antibody in a seventh indication marked the first time the regulator had authorized a biologic in COPD. The FDA approved Dupixent on the strength of clinical data showing the drug reduces exacerba...
Dupixent is a brand (trade) name for dupilumab which may be used to reduce inflammation associated with asthma, eczema, chronic rhinosinusitis, COPD, eosinophilic esophagitis, or prurigo nodularis. Dupixent (dupilumab) blocks the inflammatory response by binding to the interleukin-4Rα subunit which ...
全球合作协议共同开发该药物用于由2型炎症驱动的多种炎症性疾病的治疗,包括:伴有鼻息肉的慢性鼻窦炎(III期临床)、儿童哮喘(III期临床)、儿童特应性皮炎(III期临床)、青少年特应性皮炎(III期)、嗜酸性粒细胞性食管炎(III期)、草过敏(II期临床)、花生过敏(II期临床),未来的开发项目还包括慢性阻塞性肺病(COPD)...
Join the community. Try Seeking Alpha for free by creating an account »Create Free AccountSeeking Alpha - Power to Investors Power to Investors Follow us Download app Account Account Login Manage My Portfolio Privacy Create Portfolio Portfolio Health Check Alert Preferences Subsc...